Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX), a biopharmaceutical company focused on developing breakthrough treatments for human disease, updated its drug development progress and reported financial results for the three months ended March 31, 2014. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) weekly performance is -7.19%.On last trading day company shares ended up $1.42. Analysts mean target price for the company is $2.83. Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) distance from 50-day simple moving average (SMA50) is -14.80%.
Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) from a “neutral” rating to an “outperform” rating in a research note on Wednesday, They set a “buy” rating and a $11.00 price target on the stock. Finally, analysts at Piper Jaffray upgraded shares of ZIOPHARM Oncology to a “neutral” rating in a research note on Tuesday.ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shares advanced 9.12% in last trading session and ended the day on $3.23. ZIOP return on assets is -102.80%. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) quarterly performance is -19.85%.
May 6, 2014 Sangamo BioSciences, Inc. (NASDAQ: SGMO) reported first quarter 2014 financial results and accomplishments. For the first quarter ended March 31, 2014, Sangamo reported a consolidated net loss of $7.6 million, or $0.12 per share, compared to a net loss of $6.9 million, or $0.13 per share, for the same period in 2013. As of March 31, 2014, the Company had cash, cash equivalents, marketable securities and interest receivable of $244.2 million.Sangamo Biosciences, Inc. (NASDAQ:SGMO) shares moved up 5.12% in last trading session and was closed at $12.31, while trading in range of $11.47 – $12.50. Sangamo Biosciences, Inc. (NASDAQ:SGMO) year to date (YTD) performance is -11.38%.
XOMA Corp (NASDAQ:XOMA) shares moved higher after the company reported wider-than-expected loss per share in the Q1 of 2014 and slower-than-expected patient enrolment in two phase III studies being conducted with gevokizumab. The company posted a loss of 23 cents per share, broader than the Zacks Consensus Estimate of a loss of 19 cents per share and the last year loss of 15 cents per share. Shares increased on Friday almost 6% after the news.XOMA Corp (NASDAQ:XOMA) ended the last trading day at $3.64. Company weekly volatility is calculated as 11.02% and price to cash ratio as 3.20. XOMA Corp (NASDAQ:XOMA) showed a negative weekly performance of -15.35%.